Отчет об анализе размера, доли и тенденций мирового рынка рака пищевода – обзор отрасли и прогноз до 2031 года

Анализ рынка рака пищевода

Рынок рака пищевода переживает значительный рост, обусловленный ростом заболеваемости, усовершенствованием методов лечения и повышением осведомленности о ранней диагностике. Рынок подкрепляется надежным ассортиментом инновационных методов лечения, включая целевую терапию и иммунотерапию. Недавние разработки, включая одобрение FDA новых препаратов, таких как Opdivo (ниволумаб) и комбинаций с Yervoy (ипилимумаб) для лечения плоскоклеточного рака пищевода на поздних стадиях, подчеркивают переход к персонализированной медицине. Кроме того, рост государственных инициатив и финансирования исследований усиливает разработку технологий ранней диагностики, что приводит к улучшению результатов лечения пациентов. На рынке также наблюдается растущий акцент на паллиативной помощи и поддерживающей терапии, что отражает более целостный подход к лечению пациентов. Кроме того, сотрудничество фармацевтических компаний и научно-исследовательских институтов ускоряет разработку эффективных методов лечения, делая рынок рака пищевода динамичной и быстро развивающейся областью, которая обещает лучшее управление и результаты лечения в ближайшие годы.

Размер рынка рака пищевода

Объем мирового рынка рака пищевода в 2023 году оценивался в 1,34 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 2,57 млрд долларов США, при среднегодовом темпе роста 8,50% в прогнозируемый период с 2024 по 2031 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Тенденции рынка рака пищевода

« Растущее использование таргетной терапии»

Рынок рака пищевода переживает значительный рост, обусловленный ростом заболеваемости и усовершенствованием методов лечения. Одной из заметных тенденций является рост таргетной терапии, которая улучшает результаты лечения пациентов и предлагает более персонализированные подходы к лечению. Например, одобрение трастузумаба дерукстекана (Enhertu) в 2022 году для HER2-положительного рака пищевода изменило ландшафт лечения, предоставив новый вариант для пациентов, у которых ранее был ограниченный выбор. Такая терапия показала многообещающие результаты, а клинические испытания показали положительный уровень ответа, что отражает ее потенциал для улучшения показателей выживаемости. Кроме того, растущее внедрение технологий жидкой биопсии позволяет проводить раннее выявление и мониторинг в реальном времени ответов на лечение, что еще больше улучшает ведение пациентов. Рынок рака пищевода готов к росту, обусловленному этими инновационными методами лечения и растущим вниманием к персонализированной медицине.

Область применения отчета и сегментация рынка рака пищевода

Esophageal Cancer Market Definition

Esophageal cancer is a type of cancer that originates in the esophagus, the long, hollow tube that connects the throat to the stomach. It occurs when cells in the esophagus undergo genetic mutations that lead to uncontrolled growth and division, forming tumors. There are two main types of esophageal cancer: adenocarcinoma, which usually develops in the lower part of the esophagus and is often associated with chronic acid reflux and Barrett's esophagus, and squamous cell carcinoma, which typically occurs in the upper and middle sections and is linked to factors such as smoking and heavy alcohol consumption. Esophageal cancer symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn.

Esophageal Cancer Market Dynamics

Drivers

• Increasing Incidence Rates of Esophageal Cancer

Increasing incidence rates of esophageal cancer are significantly influenced by rising prevalence of risk factors such as obesity, gastroesophageal reflux disease (GERD), and smoking. The American Cancer Society reported that the incidence of esophageal cancer has nearly tripled in the last four decades, with an estimated 20,640 new cases diagnosed in the U.S. in 2023. Research indicates that obesity is a key contributor, with studies showing that individuals with a body mass index (BMI) over 30 have a twofold increased risk of developing esophageal adenocarcinoma compared to those with a normal weight. In addition, the prevalence of GERD, which affects approximately 20% of the U.S. population, further heightens the risk of esophageal cancer due to chronic inflammation and damage to the esophageal lining. Such alarming trends underscore the urgent need for effective treatment options and preventive strategies in managing esophageal cancer, ultimately driving the market expansion.

• Rising Healthcare Expenditure

Rising healthcare expenditure is a significant driver of growth in the esophageal cancer market, as patients increasingly seek advanced treatment options and comprehensive care. According to a report from the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending reached approximately USD 4.3 trillion in 2021, with oncology services accounting for a substantial portion of this expenditure. This trend reflects a growing investment in cancer research, treatment technologies, and patient care initiatives. Furthermore, with more hospitals and clinics adopting cutting-edge technologies such as robotic surgery and personalized treatment plans, patients are more such asly to receive timely and effective care for esophageal cancer. Such increased spending on healthcare enhances treatment accessibility and improves patient outcomes, further driving market growth.

Opportunities

• Growing Advancements in Treatment Options

Advancements in treatment options for esophageal cancer are significantly enhancing patient outcomes, particularly through innovations in immunotherapies and minimally invasive surgical techniques. For Instance, the development of nivolumab (Opdivo), an immune checkpoint inhibitor approved for esophageal squamous cell carcinoma improves overall survival rates. In addition, the adoption of minimally invasive techniques such as endoscopic submucosal dissection (ESD) allows for the removal of early-stage tumors with less trauma compared to traditional surgery, leading to quicker recovery times and reduced hospital stays. The integration of such advanced therapies expands treatment options for esophageal cancer patients and create opportunities for further market growth, as healthcare providers increasingly incorporate cutting-edge interventions to improve care quality and effectiveness.

• Growing Awareness of Symptoms and Risk Factors

Growing awareness of esophageal cancer symptoms and risk factors has significantly contributed to earlier diagnoses, enhancing treatment outcomes for patients. Initiatives aimed at educating the public about the risks associated with obesity, smoking, and gastroesophageal reflux disease (GERD) have been pivotal in this regard. In addition, advancements in diagnostic technologies, such as high-definition endoscopy and liquid biopsy, are enabling healthcare providers to detect esophageal cancer at more treatable stages. Liquid biopsy, which allows for the non-invasive analysis of circulating tumor DNA, has shown promise in identifying cancer recurrence earlier than traditional methods. Such developments facilitate timely intervention and contribute to improved survival rates, further emphasizing the importance of awareness and early detection in broadening opportunities for esophageal cancer market.

Restraints/Challenges

• High Treatment Cost

High treatment costs represent a significant barrier in the esophageal cancer market, particularly regarding advanced treatment options such as immunotherapies and targeted therapies. For instance, trastuzumab deruxtecan (Enhertu), a groundbreaking therapy for HER2-positive esophageal cancer, can be prohibitively expensive, placing immense strain on patients and healthcare systems, especially in countries with high out-of-pocket expenses for medications. This financial burden is particularly challenging for patients lacking comprehensive insurance coverage, as many may struggle to afford these innovative therapies. Consequently, the high costs associated with effective treatment options can limit access, potentially resulting in poorer health outcomes for those diagnosed with esophageal cancer.

• Delays in Regulatory Approvals

Regulatory hurdles significantly challenge the esophageal cancer market, as stringent requirements can delay the approval and market entry of new therapies. For example, navigating the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval processes can take several years, often prolonging the timeline for innovative treatments to reach patients. Such prolonged timeline can be particularly detrimental in oncology, where advancements are critical for improving patient outcomes, as patients with advanced disease may not have the luxury of waiting for new therapies, hindering the overall market expandion.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Esophageal Cancer Market Scope

The market is segmented on the basis of type, treatment type, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Esophageal Squamous-Cell Carcinoma
• Esophageal Adenocarcinoma
• Others

Treatment Type

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Immunotherapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Esophageal Cancer Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment type, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific region leads the market, largely attributed to the rapid development of healthcare facilities that enhance access to essential services. A significant presence of generic manufacturers also supports market growth by providing affordable treatment options. Furthermore, increasing government initiatives and the establishment of specialist communities are driving advancements in healthcare delivery, contributing to the region's dominance in the market.

North America is anticipated to experience the most significant market growth, driven by its position as a global leader in research and development activities. The region benefits from a well-established regulatory approval framework that facilitates the introduction of new treatments. In addition, the rising incidence of esophageal cancer is fueling demand for innovative therapies and technologies, further contributing to market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Esophageal Cancer Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Esophageal Cancer Market Leaders Operating in the Market Are:

• Johnson & Johnson Services, Inc. (U.S.)
• Cipla (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (США)
• Merck KGaA (Германия)
• LEO Pharma A/S (Дания)
• Bausch Health Companies Inc. (Канада)
• Sun Pharmaceutical Industries Ltd. (Индия)
• Ауробиндо Фарма (Индия)
• Люпин (Индия)
• Hikma Pharmaceuticals PLC (Великобритания)
• Amneal Pharmaceuticals LLC (США)
• Pfizer Inc. (США)
• Viatris Inc. (США)
• Новартис АГ (Швейцария)
• Компания Bristol-Myers Squibb (США)
• GSK plc (Великобритания)
• Bayer AG (Германия)
• Otsuka America Pharmaceutical, Inc. (Япония)
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Китай)

Последние разработки на рынке лечения рака пищевода

• В сентябре 2024 года Lumicell, Inc., частная компания, занимающаяся созданием инновационных технологий визуализации с использованием флуоресценции для обнаружения раковых тканей во время хирургических операций, объявила о получении контракта на исследования инноваций малого бизнеса (SBIR) первой фазы от Национального института рака (NCI) при Национальных институтах здравоохранения (NIH). Этот контракт будет поддерживать разработку новой гибкой эндоскопической платформы, которая объединяет дальнюю красную флуоресценцию и визуализацию в отраженном свете для выявления предраковых поражений и ранней стадии аденокарциномы пищевода (EAC) во время стандартной клинической эндоскопии.
• В мае 2022 года Управление по контролю за продуктами и лекарствами США (FDA) выдало компании Bristol Myers Squibb одобрение на два ее продукта: Opdivo (ниволумаб) для внутривенных инъекций и комбинацию Opdivo с Yervoy (ипилимумаб) в качестве терапии первой линии для пациентов с диагнозом запущенный или метастатический плоскоклеточный рак пищевода (ESCC).

SKU-53749